Tianshu Liu
Postdoctoral Associate in Cell BiologyAbout
Research
Publications
2025
Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial
Zhou H, Lv M, Li W, Wang Y, Wu J, Liu Q, Liu T, Li Q. Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial. The Oncologist 2025, 30: oyaf341. PMID: 41056437, PMCID: PMC12611345, DOI: 10.1093/oncolo/oyaf341.Peer-Reviewed Original ResearchConceptsNon-breast solid tumorsMedian progression-free survivalMedian overall survivalCirculating tumor DNAHuman epidermal growth factor receptor 2Solid tumorsHuman epidermal growth factor receptor 2 overexpressionAnalysis of circulating tumor DNAGrade 3 adverse eventsLonger median overall survivalEpidermal growth factor receptor 2Disease control rateSafety of pyrotinibProgression-free survivalHER2-Targeted TherapyMedian Follow-UpBiomarkers of efficacyBasket trialsCopy number burdenRECIST versionOverall survivalPrimary endpointZhongshan HospitalEfficacy analysisTumor DNAThe first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.
Fu S, Shen L, Lu S, Sommerhalder D, Liu T, Spira A, Li J, Yu Y, Li W, Li J, Song B, Dong C, Lai L, Ma S, Shang E, Zhong B, Zhang T. The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. Journal Of Clinical Oncology 2025, 43: 3083-3083. DOI: 10.1200/jco.2025.43.16_suppl.3083.Peer-Reviewed Original ResearchMaximum tolerated doseNon-small cell lung cancer modelTreatment related adverse eventsPancreatic ductal carcinomaColorectal cancerSolid tumorsFirst-in-human phase 1/2 studyRecommended phase 2 doseTumor cells in vitroMedian prior linesPhase 1/2 studyPhase 1b/2 studyPhase 2 dosePhase 2 partRelated grade 3Dose-limiting toxicityAdvanced solid tumorsDose-escalation partEvaluated dose rangeNausea and diarrheaInhibited tumor growthLung cancer modelRelated adverse eventsStandard of careCells in vitroPIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma
Guo M, Chen S, Sun J, Xu R, Qi Z, Li J, Zhou L, Fang Y, Liu T, Xia J. PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma. Advanced Science 2025, 12: e04372. PMID: 40405713, PMCID: PMC12376573, DOI: 10.1002/advs.202504372.Peer-Reviewed Original ResearchNrf2-dependent transcriptionHepatocellular carcinomaKinase-independent mannerProgrammed Cell DeathKelch domain of Kelch-like ECH-associated protein 1Sensitizes HCC cells to sorafenibHepatocellular carcinoma tumorigenesisIron-dependent formInduced sorafenib resistanceKelch domainPIP5K1AKelch-like ECH-associated protein 1Inhibit HCC growthCells to sorafenibECH-associated protein 1Cell deathSorafenib-induced ferroptosisEfficacy of sorafenibHepatocellular carcinoma patientsFerroptosis resistanceCancer-related mortalityUbiquitination degradationFerroptosis inducersProtein 1Stabilize Nrf2Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring
Jiao H, Lin S, Gu J, Jiang D, Cui P, Huang Z, Fang Y, Wang H, Lin M, Tang H, Jiang T, Lin G, Zhang S, Yin H, Liang F, Wang J, Fan X, Qiu F, Yang Y, Li Z, Li B, Xiang J, Leng X, Han Y, Li C, Ai L, Hou Y, Wang G, Zhang Z, Cai S, Liu T, Yin J, Tan L. Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring. Molecular Cancer 2025, 24: 143. PMID: 40375301, PMCID: PMC12079821, DOI: 10.1186/s12943-025-02332-8.Peer-Reviewed Original ResearchConceptsCirculating tumor DNAOesophageal squamous cell carcinomaPathological complete responseResectable oesophageal squamous cell carcinomaPathologic complete response rateR0 resection ratePhase 2 studySquamous cell carcinomaNivolumab groupResection rateCell carcinomaLocally Advanced Squamous Cell CarcinomaTreating oesophageal squamous cell carcinomaTwo-year overall survival ratesCirculating tumor DNA dynamicsMulticenter phase 2 studyMulticentre phase 2 studyAdvanced squamous cell carcinomaCirculating tumor DNA levelsEvent-free survival rateMedian follow-up durationEffect of adjuvant therapyLong-term survival dataMonitoring minimal residual diseaseIntention-to-treat populationEfficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Qi C, Shen L, Andre T, Chung H, Cannon T, Garralda E, Italiano A, Rieke D, Liu T, Burcoveanu D, Neu N, Mussi C, Xu R, Hong D, Drilon A, Berlin J. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal Of Cancer 2025, 220: 115338. PMID: 40068370, PMCID: PMC12517377, DOI: 10.1016/j.ejca.2025.115338.Peer-Reviewed Original ResearchTreatment-related adverse eventsSafety of larotrectinibMicrosatellite instability-highGI cancersMedian duration of responseNext-generation sequencing testMedian overall survivalProgression-free survivalDuration of responseNTRK gene fusionsOverall response rateFirst-in-classOverall survivalMedian durationTRK inhibitorsSolid tumorsTumor typesAdverse eventsExtended survivalLarotrectinibGastrointestinal cancerPatientsHepatic cancerResponse rateCancerNovel cancer stem cell-targeted retinoid ZSH-512 impedes colorectal cancer progress via KDM3A-mediated epigenetic reprogramming
Li S, Zhao W, An Q, Wang L, Zhu M, Ni J, Huang X, Jiang Y, Li M, Hou J, Yu Y, Yu S, Wei L, Jiao H, Liu T, Cao X. Novel cancer stem cell-targeted retinoid ZSH-512 impedes colorectal cancer progress via KDM3A-mediated epigenetic reprogramming. The Innovation 2025, 6: 100831. PMID: 40470327, PMCID: PMC12130993, DOI: 10.1016/j.xinn.2025.100831.Peer-Reviewed Original ResearchPatient-derived organoidsCancer stem cellsColorectal cancerPresence of cancer stem cellsEpigenetic reprogrammingAdvanced colorectal cancerStemness-related signaling pathwaysTransposase-accessible chromatin sequencingColorectal cancer progressionLiver metastasesPredictive biomarkersRecurrence rateTumor xenograftsIntegrated analysisDrug resistanceMultiple therapiesMouse modelTumor formationATAC-seqCancer progressionChromatin sequencingKDM3A expressionMetastasisRNA-seqStem cellsFirst-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
Shen L, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Hu N, McCraith S, Liu T. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. Journal Of Clinical Oncology 2025, 43: 392-392. DOI: 10.1200/jco.2025.43.4_suppl.392.Peer-Reviewed Original ResearchBlinded independent central reviewObjective response rateProgression-free survivalCombined positive scorePD-L1CheckMate 649Overall survivalFollow-upSurvival benefitPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Long-term survival benefitStudy populationDual primary endpointsDeath-ligand 1Gastroesophageal junction cancerDuration of responseAdvanced gastric cancerIndependent central reviewOS ratesJunction cancerCentral reviewPrimary endpointFirst-lineNivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.
Janjigian Y, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Elimova E, Bruges R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, McCraith S, Hu N, Zhang J, Shitara K. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649. Journal Of Clinical Oncology 2025, 43: 398-398. DOI: 10.1200/jco.2025.43.4_suppl.398.Peer-Reviewed Original ResearchProgression-free survivalBlinded independent central reviewObjective response rateCombined positive scorePD-L1Overall survivalFollow-upCheckMate 649OS ratesPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Anti-PD-1Death-ligand 1Duration of responseIndependent central reviewMinimum follow-upFollow-up resultsLong-term survivalOS benefitCentral reviewCombination therapyFirst-linePrimary endpointNivolumabFamitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Ai L, Li Q, Zhang S, Dong Y, Yang M, Li J, Pan Y, Yuan Y, Yi S, Wang J, Cheng Y, Feng J, Gao S, Wang X, Qu S, Zhang X, Lu J, Xiu P, Wang S, Yang X, Yu Y, Liu T. Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study. The Innovation 2025, 6: 100745. PMID: 39872476, PMCID: PMC11763884, DOI: 10.1016/j.xinn.2024.100745.Peer-Reviewed Original ResearchProgression-free survivalDuration of responseAdvanced colorectal cancerOverall survivalColorectal cancerMedian duration of responseMedian progression-free survivalMetastatic colorectal cancer patientsTreatment-related adverse eventsMedian follow-up timeMedian overall survivalMetastatic solid tumorsPD-1 antagonistsFollow-up timeCohort of patientsAnti-angiogenic agentsColorectal cancer patientsInhibition of angiogenesisPD-1Immune checkpointsMetastatic diseaseBasket studyMedian durationPrimary endpointSystemic treatment
2024
Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial
Wu J, Zhang S, Yu S, An G, Wang Y, Yu Y, Liang L, Wang Y, Xu X, Xiong Y, Shao D, Shi Z, Li N, Wang J, Jin D, Liu T, Cui Y. Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial. Nature Communications 2024, 15: 8876. PMID: 39406730, PMCID: PMC11480398, DOI: 10.1038/s41467-024-53109-4.Peer-Reviewed Original ResearchConceptsEsophageal squamous cell carcinomaAdvanced gastric adenocarcinomaSquamous cell carcinomaTyrosine kinase inhibitorsGastric adenocarcinomaVariant allele frequencyAnlotinib hydrochlorideCell carcinomaVascular endothelial growth factor inhibitorsAnti-PD-1 antibodySafety of nivolumabAnti-PD-1Disease control rateMedian overall survivalProgression-free survivalGrowth factor inhibitorsPhase II trialOverall response rateOASIS trialPD-1Second-lineOverall survivalImmune signaturesII trialFactor inhibitors